We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

102 hedge funds and large institutions have $316M invested in Viracta Therapeutics, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 28 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

157% more call options, than puts

Call options by funds: $10.9M | Put options by funds: $4.26M

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

46% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 28

7% more funds holding

Funds holding: 95 → 102 (+7)

0% less capital invested

Capital invested by funds: $317M → $316M (-$1.03M)

Holders
102
Holders Change
+7
Holders Change %
+7.37%
% of All Funds
2.93%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
18
Increased
41
Reduced
28
Closed
11
Calls
$10.9M
Puts
$4.26M
Net Calls
+$6.67M
Net Calls Change
+$1.5M

Top Buyers

Rank Fund Capital Flow
1
EAM
Eagle Asset Management
Florida
+$6.44M
2
NIP
Nicholas Investment Partners
California
+$1.71M
3
Stifel Financial
Stifel Financial
Missouri
+$1.35M
4
U
UBS
Switzerland
+$1.29M
5
PCM
Palisade Capital Management
New Jersey
+$1.26M

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$5.14M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.59M
3
PC
PointState Capital
New York
-$2.31M
4
GPP
Great Point Partners
Connecticut
-$1.28M
5
EI
EAM Investors
California
-$1.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
26
Federated Hermes
Pennsylvania
$2.03M -$907K -782 -35%
NIP
27
Nicholas Investment Partners
California
$2.01M +$1.71M +1,470 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.7M +$492K +424 +52%
BA
29
BlackRock Advisors
Delaware
$1.53M -$599K -516 -32%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$1.46M -$298K -257 -19%
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$1.39M +$1.07M +918 +966%
SGAM
32
Smith Group Asset Management
Texas
$1.33M -$52.2K -45 -4%
RPAM
33
Rhenman & Partners Asset Management
Sweden
$1.31M +$297K +256 +36%
First Eagle Investment Management
34
First Eagle Investment Management
New York
$1.3M -$109K -94 -9%
EAM
35
EverPoint Asset Management
Connecticut
$1.3M +$1.1M +952 New
Geode Capital Management
36
Geode Capital Management
Massachusetts
$1.26M +$68.5K +59 +7%
TCIM
37
TIAA CREF Investment Management
New York
$1.19M +$240K +207 +31%
Ameriprise
38
Ameriprise
Minnesota
$1.17M +$213K +184 +27%
DA
39
DSC Advisors
Illinois
$1.14M +$966K +833 New
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$1.09M – – –
MAA
41
Managed Account Advisors
New Jersey
$1.07M +$144K +124 +19%
BIM
42
BlackRock Investment Management
Delaware
$930K +$217K +187 +38%
MCM
43
Munder Capital Management
Michigan
$811K -$24.4K -21 -3%
EIM
44
Essex Investment Management
Massachusetts
$760K -$399K -344 -38%
PI
45
Putnam Investments
Massachusetts
$748K – – –
Charles Schwab
46
Charles Schwab
California
$716K +$102K +88 +20%
TD Asset Management
47
TD Asset Management
Ontario, Canada
$703K – – –
AIG
48
American International Group
New York
$692K +$71.9K +62 +14%
IGIM
49
I.G. Investment Management
Manitoba, Canada
$652K -$730K -629 -57%
EAM
50
Eventide Asset Management
Massachusetts
$599K – – –
1
2
3 4 5

VIRX Hedge Fund Activity: Q2 2014 in Review

102 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2014, worth a combined $316M — down 0.32% from $317M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new VIRX positions and 11 closed out — a net gain of 7 holders — while 41 added to existing stakes and 28 trimmed.

The largest buyer was Eagle Asset Management, opening a new position worth an estimated $6.44M. The largest seller was Farallon Capital Management, cutting an estimated $5.14M.

  • 102 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2014, up from 95 in Q1 2014.
  • Funds reported $316M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2014, down 0.32% quarter-over-quarter.
  • 18 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2014 and 11 closed out, a net change of +7 holders.
  • The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2014 was Eagle Asset Management, an estimated $6.44M added.
  • The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2014 was Farallon Capital Management, an estimated $5.14M sold.

Based on aggregated 13F filings for Q2 2014.